JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265805

Human MPRIP knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

MPRIP KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 4 and Insertion of the selection cassette in exon 4. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.

View Alternative Names

9530046C02, AA536749, AI647711, C76423, KIAA0864, M-RIP, MGC67316, MPRIP_HUMAN, Myosin phosphatase Rho-interacting protein, RP23-180B18.4, Rho-interacting protein 3, Rhoip3, mKIAA0864, p116 Rho-interacting protein, p116Rip

2 Images
Sanger Sequencing - Human MPRIP knockout HeLa cell line (AB265805)
  • Sanger seq

Unknown

Sanger Sequencing - Human MPRIP knockout HeLa cell line (AB265805)

Allele-1 : Insertion of the selection cassette in exon 4.

Sanger Sequencing - Human MPRIP knockout HeLa cell line (AB265805)
  • Sanger seq

Unknown

Sanger Sequencing - Human MPRIP knockout HeLa cell line (AB265805)

Allele-2 : 1 bp deletion in exon 4.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 4 and Insertion of the selection cassette in exon 4

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265805-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265805 Human MPRIP knockout HeLa cell line", "number":"AB265805-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265805-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265805-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265805 Human MPRIP knockout HeLa cell line", "number":"AB265805-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265805-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265805-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265805 Human MPRIP knockout HeLa cell line", "number":"AB265805-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265805-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265805 Human MPRIP knockout HeLa cell line", "number":"AB265805-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
MPRIP
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

MPRIP also known as Myosin Phosphatase Rho Interacting Protein or p116Rip is an important player in the regulation of the actin cytoskeleton. This protein weighs approximately 116 kDa and is expressed in a variety of tissues including the brain heart and testis. It interacts with the regulatory subunit of myosin phosphatase influencing actin filament dynamics by modulating the interaction between actin and myosin.
Biological function summary

MPRIP serves a critical role in the modulation of actin cytoskeleton rearrangement. It is part of a multi-protein complex that includes myosin phosphatase which is essential for dephosphorylation of myosin light chains. By binding directly to the myosin phosphatase complex MPRIP ensures proper regulation of actin-myosin interactions which are integral to cellular processes such as migration division and shape maintenance.

Pathways

MPRIP plays an important role within the RhoA signaling pathway and the regulation of cytoskeletal rearrangements. It facilitates the interaction between RhoA and myosin phosphatase leading to the deactivation of contractility. Another important protein involved is ROCK as MPRIP counteracts ROCK-induced phosphorylation of myosin light chain therefore influencing cell contractility and motility.

MPRIP dysregulation has implications in cardiovascular diseases and cancer. Its connection with proteins like ROCK and RhoA highlights its role in these pathologies. In cardiovascular diseases improper MPRIP function can lead to aberrant vascular smooth muscle contraction while in cancer altered MPRIP activity may contribute to changes in cell migration and invasion affecting cancer progression and metastasis.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com